313 related articles for article (PubMed ID: 22912540)
1. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
Cao DX; Li ZJ; Jiang XO; Lum YL; Khin E; Lee NP; Wu GH; Luk JM
World J Gastroenterol; 2012 Aug; 18(30):3923-30. PubMed ID: 22912540
[TBL] [Abstract][Full Text] [Related]
2. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression.
Lin CN; Wang CJ; Chao YJ; Lai MD; Shan YS
BMC Cancer; 2015 Mar; 15():128. PubMed ID: 25872762
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of osteopontin expression in human gastric carcinoma.
Higashiyama M; Ito T; Tanaka E; Shimada Y
Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin promotes the progression of gastric cancer through the NF-κB pathway regulated by the MAPK and PI3K.
Liu J; Liu Q; Wan Y; Zhao Z; Yu H; Luo H; Tang Z
Int J Oncol; 2014 Jul; 45(1):282-90. PubMed ID: 24756245
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
6. Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.
Kiss T; Jámbor K; Koroknai V; Szász I; Bárdos H; Mokánszki A; Ádány R; Balázs M
Pathol Oncol Res; 2021; 27():581395. PubMed ID: 34257527
[TBL] [Abstract][Full Text] [Related]
7. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
[TBL] [Abstract][Full Text] [Related]
8. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
Zhang X; Tsukamoto T; Mizoshita T; Ban H; Suzuki H; Toyoda T; Tatematsu M
Oncol Rep; 2009 Mar; 21(3):609-13. PubMed ID: 19212618
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation.
Song G; Ouyang G; Mao Y; Ming Y; Bao S; Hu T
J Cell Mol Med; 2009 Aug; 13(8B):1706-1718. PubMed ID: 19602039
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer.
Tang X; Li J; Yu B; Su L; Yu Y; Yan M; Liu B; Zhu Z
Int J Biol Sci; 2013; 9(1):55-66. PubMed ID: 23289017
[TBL] [Abstract][Full Text] [Related]
12. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
Gong M; Lu Z; Fang G; Bi J; Xue X
Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
[TBL] [Abstract][Full Text] [Related]
13. [Expression of osteopontin splice variant and its clinical significance in gastric cancer].
Sun X; Wang L; Hou W; Li Y; Liu L; Zuo W; Yu J
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):427-30. PubMed ID: 26463145
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.
Wang ZM; Cui YH; Li W; Chen SY; Liu TS
Oncol Rep; 2011 Apr; 25(4):997-1003. PubMed ID: 21286666
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of osteopontin in gastric cancer.
Imano M; Satou T; Itoh T; Sakai K; Ishimaru E; Yasuda A; Peng YF; Shinkai M; Akai F; Yasuda T; Imamoto H; Okuno K; Ito H; Shiozaki H; Ohyanagi H
J Gastrointest Surg; 2009 Sep; 13(9):1577-82. PubMed ID: 19582521
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin as a therapeutic target for cancer.
Bandopadhyay M; Bulbule A; Butti R; Chakraborty G; Ghorpade P; Ghosh P; Gorain M; Kale S; Kumar D; Kumar S; Totakura KV; Roy G; Sharma P; Shetti D; Soundararajan G; Thorat D; Tomar D; Nalukurthi R; Raja R; Mishra R; Yadav AS; Kundu GC
Expert Opin Ther Targets; 2014 Aug; 18(8):883-95. PubMed ID: 24899149
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of osteopontin would suppress angiogenesis in gastric cancer.
Tang H; Wang J; Bai F; Hong L; Liang J; Gao J; Zhai H; Lan M; Zhang F; Wu K; Fan D
Biochem Cell Biol; 2007 Feb; 85(1):103-10. PubMed ID: 17464350
[TBL] [Abstract][Full Text] [Related]
18. Role of Osteopontin in Liver Diseases.
Wen Y; Jeong S; Xia Q; Kong X
Int J Biol Sci; 2016; 12(9):1121-8. PubMed ID: 27570486
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
Kolb A; Kleeff J; Guweidhi A; Esposito I; Giese NA; Adwan H; Giese T; Büchler MW; Berger MR; Friess H
Cancer Biol Ther; 2005 Jul; 4(7):740-6. PubMed ID: 15970685
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Mutrie JC; Chambers AF; Tuck AB
Cancer Biol Ther; 2011 Oct; 12(8):680-90. PubMed ID: 21795853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
